placeholder
Importance
78
Trust
71
Urgency
30
CLINICAL TRIAL
Retatrutide hit 28.7% weight loss; PatentVest says the next fight is IP - Stock Titan
Retatrutide, an experimental weight-loss drug, showed patients lost 28.7% of their body weight in a trial. An intellectual property firm says the real competition next will be over patents as other companies try to develop similar drugs.
Analysis
Lilly's retatrutide showed bigger weight loss than today's top drugs. The next fight will be over patents as rivals try to copy the formula.
- Retatrutide patients lost 28.7% of their body weight in a trial
- PatentVest says the next battle will be over intellectual property
- Other drugmakers are working on similar weight-loss drugs
Retatrutide News1mo
Read